- Silex Systems (SLX) is looking to raise up to $40 million through a placement and share purchase plan (SPP)
- SLX has completed the placement which is raising $33 million through the issue of nearly 26 million shares at $1.27 each
- The SPP will aim to raise up to an extra $7 million, allowing eligible shareholders subscribing for shares worth up to $30,000 at $1.31 each
- The money is being used to commercialise SILEX’s laser isotope separation technology across multiple markets
- Company shares closed 7.17 per cent down at $1.39
Silex Systems (SLX) has completed an equity raise in the form of a placement to raise $33 million.
The company will issue nearly 26 million shares to investors at $1.27 per share. The issue price represents an 11.8 per cent discount to the last closing price on September 22 of $1.44 and a 17.2 per cent discount to the 30-day volume-weighted average price.
The research and development company also plans to raise an extra $7 million through a share purchase plan (SPP). Eligible shareholders will have the opportunity to subscribe for new shares worth up to $30,000 at an issue price of $1.31 each.
The SPP will be open from October 5 until October 22 and the results will be announced on the 27th.
Silex Systems plans to use the $40 million to commercialise its ‘innovative’ SILEX laser isotope separation technology across multiple markets.
Over the past few years, Silex has been developing its namesake technology for uranium enrichment with US-based exclusive licensee Global Laser Enrichment (GLE).
The company is now in the early stages of pursuing commercial applications outside of uranium, including the production of ‘Zero-Spin Silicon’ for the emerging technology of silicon-based quantum computing.
Aligning with this focus, the placement and SPP funds will primarily be used to advance a commercial pilot demonstration at GLE’s test loop facility. It will be also be used to assess and develop opportunities for advanced nuclear fuel production with GLE, scale-up of zero-spin silicon production capacity, and develop any other applications for the SILEX technology.
CEO and Managing Director Michael Goldsworthy commented on the equity raise.
“This equity raising secures Silex’s funding through to 2024 to further advance our SILEX enrichment technology commercialisation activities and to focus on the Paducah uranium production opportunity being planned by US-based exclusive licensee GLE.”
Company shares closed 7.17 per cent down at $1.39.